Smith & Nephew introduces the POLARSTEM™ cementless hip stem to the US market

Smith & Nephew introduces the POLARSTEM™ cementless hip stem to the US market

PR Newswire

LONDON, Feb. 19, 2014

LONDON, Feb. 19, 2014 /PRNewswire/ --Smith & Nephew (NYSE: SNN; LSE: SN), the
global medical technology business, today announced the US launch of its
clinically proven POLARSTEM cementless stem for total hip replacement.
Available outside the US since 2002, the versatile POLARSTEM implant is one of
the company's most popular stems globally and features a unique geometry and
surface texture.

Smith & Nephew logo.

For US surgeons who use the direct anterior approach for total hip
replacement, the POLARSTEM implant offers several design features that assist
with muscle sparing approaches. For example, the proximal portion of the stem
is wider to help reduce the possibility of movement downward into the bone.
Whereas the distal portion of the stem is shorter and features a narrower tip,
making it easier to implant through the smaller incision used in the direct
anterior approach. Lastly, the stem features an advanced surface texture of
titanium plasma and a hydroxyapatite layer.

"The POLARSTEM implant has advantages over similar style stems that are
currently on the market. The wider proximal fit and fill, as well as the
reduced distal body of the stem has allowed a better patient fit for my
patients with little to no limitations in regards to bone type or femoral
morphologies," says Dr. Jason Lang, Associate Professor of Orthopaedic Surgery
at Wake Forest University, Winston-Salem, North Carolina.

"Simply based on its excellent mid-term follow up data of 99.5% survivorship
at 5.6 years^i and the design advantages it offers for minimally invasive and
direct anterior surgeons, the POLARSTEM implant stands apart from other hip
stems," says Gaurav Agarwal, President of Orthopaedic Reconstruction for Smith
& Nephew's Advanced Surgical Devices Division. "However, when you add the
wear-reducing advantages of our proprietary VERILAST™ Technology, the final
construct truly becomes an optimal hip replacement option."

VERILAST Technology is an advanced low-friction bearing couple combining
OXINIUM™ Oxidized Zirconium, a patented ceramicised metal alloy for the
femoral head, and a cross-linked polyethylene (XLPE) cup liner for the
acetabulum. During rigorous lab testing, VERILAST Technology demonstrated 67%
less wear than the combination of cobalt chrome and XLPE.^ii In the 2013
Australian National Joint Registry, total hips utilizing the combination of
ceramicised metal on XLPE was shown to have higher survivorship rates of any
total hip construct utilizing other bearing combinations.^iii

Editor's notes:
With the direct anterior approach, an incision is made on the front of the hip
rather than the side or back. As a result, the surgeon can follow the natural
spaces between the hip joint's muscles and tendons, thereby minimizing the
damage to the surrounding soft tissues. Because there is less soft tissue that
needs to heal, patients undergoing direct anterior hip surgery reported less
postoperative pain.^iv

Additionally, because the gluteal muscles and other natural stabilizers are
left undisturbed during the direct anterior approach, it is possible for
patients to regain mobility more quickly and ultimately go home from the
hospital sooner.

About Smith & Nephew

Smith & Nephew is a global medical technology business dedicated to helping
healthcare professionals improve people's lives. With leadership positions in
Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and
Trauma & Extremities, Smith & Nephew has around 11,000 employees and a
presence in more than 90 countries. Annual sales in 2013 were more than $4.3
billion. Smith & Nephew is a member of the FTSE100 (LSE: SN, NYSE: SNN).

For more information about Smith & Nephew, please visit our corporate website, follow @SmithNephewplc on Twitter or visit
SmithNephewplc on

Forward-looking Statements
This document may contain forward-looking statements that may or may not prove
accurate. For example, statements regarding expected revenue growth and
trading margins, market trends and our product pipeline are forward-looking
statements. Phrases such as "aim", "plan", "intend", "anticipate",
"well-placed", "believe", "estimate", "expect", "target", "consider" and
similar expressions are generally intended to identify forward-looking
statements. Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual results to
differ materially from what is expressed or implied by the statements. For
Smith & Nephew, these factors include: economic and financial conditions in
the markets we serve, especially those affecting health care providers, payers
and customers; price levels for established and innovative medical devices;
developments in medical technology; regulatory approvals, reimbursement
decisions or other government actions; product defects or recalls; litigation
relating to patent or other claims; legal compliance risks and related
investigative, remedial or enforcement actions; strategic actions, including
acquisitions and dispositions, our success in performing due diligence,
valuing and integrating acquired businesses; disruption that may result from
transactions or other changes we make in our business plans or organisation to
adapt to market developments; and numerous other matters that affect us or our
markets, including those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith & Nephew has
filed with the U.S. Securities and Exchange Commission under the U.S.
Securities Exchange Act of 1934, as amended, including Smith & Nephew's most
recent annual report on Form 20-F, for a discussion of certain of these
factors. Any forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or oral
forward-looking statements attributable to Smith & Nephew are qualified by
this caution. Smith & Nephew does not undertake any obligation to update or
revise any forward-looking statement to reflect any change in circumstances or
in Smith & Nephew's expectations.

™Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark

^i Cypres, Alain, MD, Girardin, Phillippe, MD. "Mid-term results with the full
hydroxyapatite-coated POLARSTEM™ Femoral Stem", Bone & Joint Science. Vol. 03
No. 09, 2013.
^ii Parikh, P. Hill, V. Pawar and J. Sprague, "Long-term simulator wear
performance of an advanced bearing technology for THA," Orthop Res Soc, San
Antonio, TX, Jan 26-29, 2013, 1028.
^iii Australian Orthopaedic Association National Joint Replacement Registry
Annual report. Adelaide: AOA; 2013.
^iv V. Alecci, M. Valente, M. Crucil, M. Minerva, C.-M Pellegrino, D D.
Sabbadini, "Comparison of primary total hip replacements performed with a
direct anterior approach versus the standard lateral approach: perioperative
findings", Journal of Orthopaed Traumatol (2011) 12:123–129


SOURCE Smith & Nephew

Contact: Media: Joe Metzger, Smith & Nephew, +1 (978) 749-1330; or
Investor/Analyst: Phil Cowdy, Smith & Nephew, +44 (0)20 7401 7646
Press spacebar to pause and continue. Press esc to stop.